Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 3, 2021

View Archived Issues

Algernon repurposes a psychedelic drug as potential treatment for stroke

Akari announces development of its second clinical candidate, votucalis

New mouse model points to mitochondrial dynamics as key to neurodegeneration

BiomX reports first-in-human data with phage therapy candidate BX-002

Kira initiates first-in-human study of P-014 for complement-mediated diseases

FDA approves Posimir for post-surgical pain following arthroscopic subacromial decompression

CSL Behring initiates Australian study of CSL-760 to treat serious cases of COVID-19

Annamycin shows significant therapeutic benefit in metastatic osteosarcoma animal model

Cassava Sciences presents interim analysis data for simufilam in patients with Alzheimer's disease

University of Southern California and collaborators patent opioid receptor agonists

BioCardia announces pipeline updates and milestones

Phase I data presented for AXL inhibitor DS-1205c plus osimertinib in EGFR-mutated NSCLC

Curis initiates phase II LUCAS study of CA-4948 as treatment for anemia in MDS

DexTech expands preclinical program to evaluate OsteoDex in multiple myeloma

Tyvyt approved in China for first-line nonsquamous NSCLC

"Expansion sequencing" gives elbow room to in situ transcriptomics

Dual EGFR/LRG5 blockade with MCLA-158 shows promise in phase I study in metastatic CRC

Botanix reports data from phase IIa study of BTX-1801 for S. aureus nasal decolonization

UB-612 multitope peptide-based vaccine against COVID-19 enters phase II trials in Taiwan

Targeting ketohexokinase as new therapeutic strategy in NAFLD

Publication details phase III results with Gam-COVID-Vac (Sputnik V) vaccine

NSUN2 is a prognostic biomarker in NSCLC

Vaccitech begins phase Ib/IIa study of VTP-300 for chronic hepatitis B infection